fyv7 Antibody

What types of FZD7-targeting antibodies have been developed for research applications?

Several formats of FZD7-targeting antibodies have been developed for research applications:

• Humanized monoclonal antibodies: Such as SHH002-hu1, which has been designed with extremely high affinity for FZD7 and demonstrated ability to specifically target FZD7-positive cells and tumor tissues .

• Single-chain variable fragments (scFv): These antibody fragments contain the variable regions of heavy and light chains connected by a flexible peptide linker. The anti-FZD7 scFv (approximately 31 kDa) has demonstrated significant binding capacity to FZD7-expressing cells and potent anti-cancer effects .

• Recombinant antibody fragments: Produced in expression systems like E. coli BL21 (DE3), these can be designed using bioinformatics approaches to optimize binding and therapeutic potential .

Each antibody format offers distinct advantages depending on the research application, with full-length humanized antibodies generally providing longer half-lives and effector functions, while scFv fragments offer better tissue penetration and potentially reduced immunogenicity.

How can researchers verify the specificity of anti-FZD7 antibodies?

Verification of anti-FZD7 antibody specificity requires multiple complementary approaches:

• Flow cytometry: Analyze binding capacity to FZD7-expressing cells (e.g., MDA-MB-231) versus low-expressing control cells (e.g., SKBR-3). Significant differences in binding percentages (e.g., 21.5% binding to MDA-MB-231 cells versus 0.54% to SKBR-3 cells) indicate specificity .

• Immunofluorescence (IF) assay: Use cells with different FZD7 expression levels, including:

  • Cells with FZD7 overexpression (Fzd7 OE)

  • Vector control cells

  • Blank control cells
    Specific binding is visualized using fluorescently labeled secondary antibodies (e.g., Alexa Fluor 647) .

• Western blotting: Verify expression of anti-FZD7 fragments at the expected molecular weight (e.g., 31 kDa for scFv) .

• Biolayer interferometry (BLI) assay: Quantify binding affinity and kinetics of antibody-antigen interactions .

• Near-infrared (NIR) imaging: Evaluate targeting ability of labeled antibodies in vivo, particularly in tumor tissues versus normal tissues .

These methods collectively provide robust validation of antibody specificity and targeting capability.

What are the recommended methodologies for evaluating FZD7 antibody efficacy in cancer research?

Evaluating FZD7 antibody efficacy requires a multi-faceted approach addressing various aspects of cancer biology:

• Cell viability and proliferation:

  • MTT assay: Quantifies metabolically active cells, revealing antiproliferative effects (e.g., 73.7% induced apoptosis in MDA-MB-231 cells vs. 29.5% in low-FZD7 SKBR-3 cells) .

  • Colony formation assays: Assess long-term growth inhibition effects.

• Apoptosis assessment:

  • Annexin V/PI assays: Distinguish early and late apoptotic cells following antibody treatment .

  • Western blot analysis of apoptotic markers (caspases, PARP cleavage).

• Migration and invasion inhibition:

  • Transwell migration assays: Quantify inhibitory effects (up to 76% inhibition in MDA-MB-231 cells) .

  • Invasion assays with Matrigel: Measure reduced invasiveness (up to 58% reduction observed) .

  • Scratch/wound healing assays: Monitor cell motility over time.

• Molecular pathway analysis:

  • Luciferase reporter assays: Measure Wnt/β-catenin signaling activity .

  • Western blotting: Analyze expression of signaling proteins in the Wnt pathway.

  • qRT-PCR: Evaluate changes in target gene expression.

• In vivo studies:

  • Xenograft models: Assess tumor growth inhibition.

  • Secondary xenograft models: Evaluate effects on tumor-initiating capacity .

  • Near-infrared imaging: Track antibody localization to tumor tissues .

These complementary methods provide comprehensive insights into the mechanisms and efficacy of FZD7 antibodies against cancer progression.

How should researchers design experimental controls when testing FZD7 antibodies?

Proper control design is critical for rigorous evaluation of FZD7 antibody effects:

• Cell line controls:

  • High FZD7-expressing lines (e.g., MDA-MB-231, MDA-MB-468)

  • Low FZD7-expressing lines (e.g., SKBR-3) as negative controls

  • FZD7-overexpressing cell lines via gene transfection as positive controls

  • Vector-transfected cells as transfection controls

• Antibody controls:

  • Isotype control antibodies (matching class but irrelevant specificity)

  • Commercial anti-FZD7 antibodies with known properties as reference standards

  • Non-humanized parent antibodies when testing humanized versions

• Treatment controls:

  • Dose-response studies with varying antibody concentrations

  • Time-course experiments to determine optimal treatment duration

  • Combination treatments (e.g., with Bevacizumab) compared to single-agent treatments

• Pathway validation controls:

  • Known Wnt/β-catenin pathway inhibitors as positive controls

  • siRNA/shRNA FZD7 knockdown to compare with antibody-mediated inhibition

  • Recombinant Wnt ligands to test competitive inhibition

• In vivo controls:

  • Vehicle-treated groups

  • Non-targeting antibody groups

  • Established therapy groups (e.g., Bevacizumab alone)

This comprehensive control strategy ensures that observed effects are specifically attributable to FZD7 antibody activity rather than experimental artifacts or non-specific effects.

What expression systems are most effective for producing recombinant anti-FZD7 antibodies?

The choice of expression system depends on the antibody format and research requirements:

• E. coli expression systems:

  • Particularly effective for scFv fragments

  • BL21(DE3) strain has been successfully used for anti-FZD7 scFv expression

  • Advantages: Cost-effective, high yield, rapid production

  • Limitations: Lack of mammalian post-translational modifications, potential endotoxin contamination

• Mammalian cell expression:

  • Preferred for full-length humanized antibodies like SHH002-hu1

  • Common cell lines: HEK293, CHO

  • Advantages: Proper folding, glycosylation, reduced immunogenicity

  • Limitations: Higher cost, longer production time

• Hybridoma technology:

  • Used for generating parent monoclonal antibodies before humanization

  • Involves fusion of antibody-producing B cells with myeloma cells

  • Advantages: Stable producer cell lines, consistent antibody production

  • Limitations: Limited to mouse antibodies initially, requiring subsequent humanization

• Optimization strategies:

  • Codon optimization for the expression host

  • Signal peptide optimization for secretion

  • Temperature and induction condition optimization

  • Purification method selection based on antibody format (e.g., protein A/G affinity for full antibodies, IMAC for His-tagged scFv)

Each system offers specific advantages, with E. coli being suitable for rapid production of antibody fragments for research purposes, while mammalian systems are preferred for therapeutic-grade antibodies requiring proper glycosylation and reduced immunogenicity.

How do FZD7 antibodies affect the Wnt/β-catenin signaling pathway in cancer cells?

FZD7 antibodies disrupt Wnt/β-catenin signaling through multiple mechanisms:

• Direct receptor blockade: FZD7 antibodies bind to the extracellular domain of the receptor, preventing interaction with Wnt ligands that would normally activate the pathway .

• Signal transduction inhibition: This blockade prevents dishevelled (DVL) protein recruitment and disrupts the β-catenin destruction complex, leading to:

  • Increased β-catenin phosphorylation and degradation

  • Reduced nuclear translocation of β-catenin

  • Decreased transcription of Wnt target genes

• Pathway verification methods:

  • Luciferase reporter assays show significantly reduced Wnt/β-catenin signaling activity following antibody treatment

  • Western blot analysis demonstrates decreased levels of active (non-phosphorylated) β-catenin

  • Immunofluorescence reveals reduced nuclear localization of β-catenin

• Downstream effects:

  • Reduced expression of Wnt target genes involved in proliferation (e.g., cyclin D1, c-Myc)

  • Decreased expression of genes involved in EMT (e.g., Snail, Twist)

  • Attenuated cancer stem cell properties

• Context-dependent inhibition:

  • More pronounced effects in hypoxic tumor microenvironments, where FZD7 expression is elevated

  • Enhanced pathway inhibition when combined with other targeted therapies like Bevacizumab

By disrupting this critical signaling pathway, FZD7 antibodies effectively suppress multiple cancer hallmarks, including proliferation, invasion, and stemness.

What is the mechanism behind the synergistic effects of combining FZD7 antibodies with anti-angiogenic therapies?

The synergistic interaction between FZD7 antibodies and anti-angiogenic therapies like Bevacizumab involves multiple complementary mechanisms:

• Hypoxia-induced FZD7 upregulation:

  • Anti-angiogenic treatments (e.g., Bevacizumab) create hypoxic conditions in tumors

  • Hypoxia significantly increases FZD7 expression in cancer cells

  • Bevacizumab-treated tumor tissues show more intense hypoxia and higher FZD7 expression, particularly in zones of low oxygen

• Counteracting adaptive resistance:

  • Anti-angiogenic therapy-induced hypoxia activates Wnt/β-catenin signaling as an adaptive survival mechanism

  • FZD7 antibodies block this compensatory pathway activation

  • This prevents cancer cells from adapting to hypoxic conditions

• Complementary targeting of different cancer cell populations:

  • Anti-angiogenic therapy targets the tumor vasculature

  • FZD7 antibodies directly target cancer cells, particularly putative cancer stem-like cells

  • This dual targeting strategy addresses multiple aspects of tumor biology

• Inhibition of Bevacizumab-induced effects:

  • Bevacizumab treatment can enhance EMT in TNBC cells

  • FZD7 antibodies (e.g., SHH002-hu1) effectively suppress this Bevacizumab-induced EMT

  • FZD7 antibodies attenuate Bevacizumab-enhanced tumor-initiating and self-renewal capacity of TNBC cells

• Enhanced anti-tumor efficacy:

  • Combination treatment significantly enhances inhibition of TNBC tumor growth compared to either agent alone

  • Combined therapy reduces the subpopulation of putative TNBC stem-like cells more effectively than monotherapy

This multi-faceted synergistic mechanism provides a strong rationale for combining these two therapeutic approaches in TNBC and potentially other FZD7-expressing cancers.

How do FZD7 antibodies impact cancer cell migration and metastatic potential?

FZD7 antibodies demonstrate significant inhibitory effects on cancer cell motility and invasion through several mechanisms:

• Direct inhibition of migration:

  • Anti-FZD7 scFv exhibits up to 76% inhibition of MDA-MB-231 cell migration in transwell assays

  • Antibodies impair cell motility as observed in scratch/wound healing assays

• Reduction of invasive capacity:

  • Anti-FZD7 scFv reduces invasion of MDA-MB-231 cells by approximately 58% in Matrigel invasion assays

  • SHH002-hu1 represses invasion of TNBC cells even in the presence of Bevacizumab, which can otherwise enhance invasiveness

• Molecular mechanisms:

  • Inhibition of epithelial-mesenchymal transition (EMT)

  • Reduced expression of EMT-associated transcription factors (Snail, Twist, ZEB1/2)

  • Increased E-cadherin expression and decreased N-cadherin/vimentin levels

  • Modulation of matrix metalloproteinases (MMPs) expression

• Cytoskeletal reorganization:

  • Altered actin cytoskeleton dynamics

  • Reduced formation of invadopodia and lamellipodia

  • Decreased focal adhesion turnover, limiting cell motility

• Microenvironmental interactions:

  • Reduced response to migratory stimuli from the tumor microenvironment

  • Decreased sensitivity to chemotactic factors

  • Impaired ability to establish the pre-metastatic niche

These multifaceted effects on cell motility and invasion machinery suggest that FZD7 antibodies could have significant potential in preventing cancer metastasis, which is the primary cause of cancer-related mortality.

How can researchers evaluate the effects of FZD7 antibodies on cancer stem-like cells?

Evaluating FZD7 antibody effects on cancer stem-like cells requires specialized methodologies:

• Cancer stem cell identification:

  • Flow cytometry for stem cell markers (e.g., CD44+/CD24-/low for breast cancer)

  • ALDH activity assays using ALDEFLUOR

  • Side population analysis based on Hoechst 33342 dye exclusion

• Functional assays for stemness:

  • Sphere formation assay: Quantifies self-renewal capacity in non-adherent conditions

  • Secondary sphere formation: Measures sustainability of self-renewal

  • Limiting dilution assays: Determines frequency of tumor-initiating cells

• In vivo stem cell assessment:

  • Secondary nude mouse xenograft models: Cells from primary tumors are re-implanted to assess tumor-initiating capacity

  • Serial transplantation studies: Test long-term self-renewal potential

  • Extreme limiting dilution analysis (ELDA): Quantifies tumor-initiating cell frequency

• Molecular analysis:

  • Expression of stemness transcription factors (SOX2, OCT4, NANOG)

  • Wnt pathway target genes associated with stemness

  • Single-cell RNA sequencing to identify stem-like cell populations

• Comparative studies:

  • Effects of FZD7 antibodies versus conventional therapies on stem-like cell populations

  • Analysis of FZD7 antibody activity under conditions that enrich for stem-like cells (e.g., hypoxia)

  • Combination therapies that simultaneously target stem and non-stem cancer cell populations

The data indicate that FZD7 antibodies like SHH002-hu1 can effectively reduce the subpopulation of putative TNBC stem-like cells and attenuate Bevacizumab-enhanced tumor-initiating and self-renewal capacity of TNBC cells , highlighting their potential in targeting therapy-resistant cancer stem cells.

What approaches should researchers use to evaluate antibody efficacy under hypoxic conditions?

Evaluating FZD7 antibody efficacy under hypoxic conditions requires specialized methodology to mimic the tumor microenvironment:

• Hypoxia induction methods:

  • In vitro hypoxia chambers (1-0.1% O₂)

  • Chemical hypoxia mimetics (CoCl₂, DFO, DMOG)

  • Bevacizumab treatment to induce physiological hypoxia in tumors

  • 3D tumor spheroids with hypoxic cores

• Hypoxia verification:

  • Immunostaining for hypoxia markers (pimonidazole, HIF-1α)

  • Oxygen-sensitive probes (e.g., optical sensors)

  • Expression analysis of hypoxia-responsive genes (CA9, VEGF, GLUT1)

• Comparative analyses:

  • Parallel treatment under normoxic vs. hypoxic conditions

  • Time-course experiments under fluctuating oxygen levels

  • Gradient hypoxia models to simulate tumor oxygen gradients

• Functional assessments under hypoxia:

  • Cell viability and proliferation assays adapted for hypoxic conditions

  • Migration/invasion assays under hypoxia

  • Therapy resistance development in hypoxic environments

  • Antibody binding studies under hypoxic versus normoxic conditions

• Molecular analyses:

  • FZD7 expression changes under hypoxia (typically increased)

  • Wnt/β-catenin pathway activity in hypoxia with and without antibody treatment

  • Evaluation of HIF-1α and β-catenin crosstalk

Research has shown that Bevacizumab treatment increases FZD7 expression in TNBC cells and tissues, particularly in zones of low oxygen . This suggests that anti-FZD7 antibodies may be particularly effective under hypoxic conditions, which are common in solid tumors and often contribute to therapy resistance.

What molecular techniques are essential for exploring the mechanism of action of FZD7 antibodies?

Understanding the mechanism of action of FZD7 antibodies requires an integrated molecular analysis approach:

• Protein-protein interaction studies:

  • Co-immunoprecipitation to detect FZD7 interactions with Wnt ligands and downstream effectors

  • Proximity ligation assays to visualize protein interactions in situ

  • Surface plasmon resonance (SPR) or biolayer interferometry (BLI) for binding kinetics

  • Hydrogen-deuterium exchange mass spectrometry to map binding epitopes

• Signaling pathway analysis:

  • Phosphorylation status of key Wnt pathway proteins (LRP5/6, DVL, GSK3β)

  • β-catenin nuclear translocation using cell fractionation and imaging

  • TCF/LEF-dependent transcriptional activity via luciferase reporter assays

  • ChIP-seq to identify genome-wide changes in β-catenin binding sites

• Global gene expression profiling:

  • RNA-seq to identify differentially expressed genes following antibody treatment

  • Pathway enrichment analysis to identify affected cellular processes

  • Single-cell RNA-seq to detect cell population-specific responses

  • Comparison with known Wnt/β-catenin target gene signatures

• Protein localization and trafficking:

  • Live-cell imaging of fluorescently tagged FZD7 and pathway components

  • Internalization assays to track antibody-induced receptor endocytosis

  • Super-resolution microscopy to visualize membrane microdomain organization

  • FRAP (fluorescence recovery after photobleaching) to analyze receptor dynamics

• In vivo mechanism validation:

  • Immunohistochemistry of tumor sections for pathway markers

  • In vivo imaging of pathway reporters

  • Patient-derived xenograft models to confirm mechanisms in clinically relevant settings

These complementary approaches provide a comprehensive understanding of how FZD7 antibodies disrupt cancer-promoting signaling pathways, guiding the development of more effective targeting strategies and combination therapies.

What are common challenges in evaluating FZD7 antibody specificity and how can they be addressed?

Researchers face several challenges when evaluating FZD7 antibody specificity:

• Cross-reactivity with other Frizzled family members:

  • Challenge: The 10 human Frizzled receptors share structural homology, particularly in the extracellular cysteine-rich domain.

  • Solution:

    • Perform binding assays against cells expressing different FZD family members

    • Use competitive binding assays with recombinant FZD extracellular domains

    • Validate with CRISPR-engineered FZD7 knockout cell lines as negative controls

• Variable target expression levels:

  • Challenge: FZD7 expression varies between cell lines and can be influenced by culture conditions.

  • Solution:

    • Quantify FZD7 expression in test cells by qRT-PCR and western blot before antibody testing

    • Use stably transfected cells with controlled FZD7 expression levels

    • Include both high-expressing (e.g., MDA-MB-231) and low-expressing (e.g., SKBR-3) cell lines

• Accessibility of binding epitopes:

  • Challenge: Receptor conformation, glycosylation, or interactions with other proteins may mask epitopes.

  • Solution:

    • Test antibody binding under different conditions (temperature, pH, detergents)

    • Evaluate binding to both native and denatured receptor forms

    • Use multiple antibodies targeting different epitopes as cross-validation

• Background signal in imaging applications:

  • Challenge: Non-specific binding can obscure true positive signals.

  • Solution:

    • Optimize blocking conditions (BSA, serum, commercial blockers)

    • Include appropriate isotype controls

    • Use secondary antibody-only controls to detect non-specific binding

    • Employ tissue clearing techniques for improved signal-to-noise in 3D samples

• Validation in different sample types:

  • Challenge: Antibody performance can vary between applications (flow cytometry, IF, IHC).

  • Solution:

    • Validate antibodies separately for each application

    • Optimize fixation and permeabilization protocols for each sample type

    • Use multiple detection methods to confirm target binding

These optimization strategies help ensure that observed effects are truly attributable to specific FZD7 targeting rather than experimental artifacts or off-target effects.

How can researchers optimize the production and purification of recombinant anti-FZD7 antibodies?

Optimizing production and purification of recombinant anti-FZD7 antibodies requires attention to several key factors:

• Expression system optimization:

  • For E. coli-expressed scFv fragments:

    • Test multiple E. coli strains (BL21(DE3), Origami, SHuffle) to improve folding

    • Optimize induction conditions (IPTG concentration, temperature, duration)

    • Consider fusion partners (thioredoxin, SUMO) to enhance solubility

    • Use periplasmic secretion signals to facilitate disulfide bond formation

  • For mammalian-expressed full antibodies:

    • Compare transient vs. stable expression systems

    • Optimize transfection reagents and conditions

    • Engineer cell lines for enhanced production (CHO, HEK293)

    • Implement fed-batch or perfusion culture systems

• Antibody design considerations:

  • Codon optimization for the expression host

  • Strategic placement of purification tags (His, FLAG)

  • Incorporation of stabilizing mutations

  • Linker optimization for scFv fragments to maintain proper folding

• Purification strategy selection:

  • For full-length antibodies:

    • Protein A/G affinity chromatography

    • Ion exchange chromatography for charge variant separation

    • Size exclusion chromatography for aggregate removal

  • For antibody fragments:

    • IMAC (immobilized metal affinity chromatography) for His-tagged proteins

    • Affinity chromatography using anti-tag antibodies

    • Optimization of elution conditions to maintain functionality

• Quality control methods:

  • SDS-PAGE and western blotting to confirm size and purity

  • Size exclusion HPLC to detect aggregates

  • ELISA to confirm binding activity

  • Mass spectrometry to verify sequence and post-translational modifications

  • Endotoxin testing for in vivo applications

• Stability enhancement:

  • Buffer optimization (pH, ionic strength, excipients)

  • Storage condition determination (-80°C, -20°C, 4°C)

  • Lyophilization protocols when appropriate

  • Addition of stabilizing agents (sugars, surfactants)

The successful expression of anti-FZD7 scFv as a single band of 31 kDa in E. coli BL21(DE3) and the generation of the humanized SHH002-hu1 antibody demonstrate that both bacterial and mammalian expression systems can be effectively employed, with the choice depending on the specific antibody format and research requirements.

What are promising future directions for FZD7 antibody research in cancer therapy?

Several emerging areas show significant potential for advancing FZD7 antibody research:

• Antibody-drug conjugates (ADCs):

  • Conjugating cytotoxic payloads to FZD7 antibodies to enhance tumor-specific drug delivery

  • Exploring cleavable versus non-cleavable linkers for optimal payload release

  • Evaluating different payloads (MMAE, DM1, SN-38) for efficacy against FZD7-expressing tumors

• Bispecific antibody development:

  • Creating bispecific antibodies targeting FZD7 and complementary targets (e.g., EGFR, HER2)

  • Developing T-cell engagers (FZD7 × CD3) to recruit immune cells to tumors

  • Designing bispecifics that simultaneously block multiple Wnt pathway components

• Combination therapy optimization:

  • Building on the synergistic effects observed with Bevacizumab

  • Exploring combinations with immune checkpoint inhibitors

  • Testing FZD7 antibodies with conventional chemotherapies

  • Investigating sequential versus concurrent administration strategies

• FZD7 antibodies in cancer immunotherapy:

  • Studying how FZD7 blockade affects the tumor immune microenvironment

  • Exploring FZD7's role in immune cell recruitment and function

  • Developing chimeric antigen receptor (CAR) T cells targeting FZD7

• Expanding beyond TNBC:

  • Investigating efficacy in other FZD7-expressing cancers (colorectal, hepatocellular, gastric)

  • Identifying biomarkers to predict response across cancer types

  • Developing companion diagnostics for FZD7 expression

• Technology integration:

  • Applying single-cell analysis to understand heterogeneous responses

  • Using patient-derived organoids for personalized therapy testing

  • Implementing AI/machine learning to predict optimal antibody design and combination strategies

These directions build upon the foundational research showing that FZD7 antibodies can inhibit tumor growth, enhance the effects of existing therapies like Bevacizumab, and target cancer stem-like cells that drive recurrence and metastasis .

What approaches can researchers use to study resistance mechanisms to FZD7-targeted therapies?

Understanding and overcoming resistance to FZD7-targeted therapies requires systematic investigation:

• In vitro resistance model development:

  • Continuous exposure to increasing antibody concentrations

  • Pulse exposure protocols mimicking clinical dosing

  • Genetic screens (CRISPR-Cas9) to identify resistance factors

  • Long-term culture under antibody selection pressure

• Molecular characterization of resistant cells:

  • Receptor mutation and expression analysis

  • Alternative Wnt receptor upregulation (other FZD family members, ROR1/2, RYK)

  • Bypass pathway activation (Hedgehog, Notch, receptor tyrosine kinases)

  • Epigenetic changes affecting FZD7 and Wnt pathway regulation

• Functional studies:

  • Binding assays to detect altered antibody-receptor interactions

  • Signaling pathway analysis in resistant versus sensitive cells

  • Migration/invasion/stemness assays to determine phenotypic changes

  • Drug combination screens to identify resistance-overcoming agents

• Clinical correlation studies:

  • Pre- and post-treatment biopsy analysis

  • Circulating tumor cell and cell-free DNA analysis during treatment

  • Patient-derived xenograft models from treatment-resistant tumors

  • Correlation of molecular features with clinical outcomes

• Overcoming resistance strategies:

  • Developing antibodies targeting different FZD7 epitopes

  • Simultaneous targeting of multiple Wnt pathway components

  • Rational combination therapies based on resistance mechanisms

  • Intermittent dosing schedules to prevent resistance development

• Computational approaches:

  • Network analysis to identify critical nodes in resistance pathways

  • Predictive modeling of resistance development

  • Virtual screening for complementary therapeutic targets

  • Analysis of large-scale genomic datasets to identify resistance biomarkers

These systematic approaches would help identify mechanisms of resistance to FZD7 antibodies and develop strategies to overcome them, ultimately improving the therapeutic potential of these promising targeted agents.